Straits Times Index
3,303.19 +10.26 (+0.31%) S&P 500
5,158.95 +31.16 (+0.61%) Dow
38,821.67 +145.99 (+0.38%) Nasdaq
16,261.99 +105.66 (+0.65%) Bitcoin USD
63,999.86 +107.02 (+0.17%) CMC Crypto 200
1,378.24 +65.61 (+5.00%)
Marinus Pharmaceuticals, Inc. (0JYL.L)
| Previous close | 1.4450 |
| Open | 1.5600 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 1.5600 - 1.5900 |
| 52-week range | 1.5600 - 11.2400 |
| Volume | |
| Avg. volume | 499 |
| Market cap | 718,767 |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference
RADNOR, Pa., May 02, 2024--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D., Chairman and Chief Executive Officer, will be participating in a fireside chat at the RBC Capital Markets 2024 Global Healthcare Conference.
- Business Wire
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024
RADNOR, Pa., May 01, 2024--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the first quarter ended March 31, 2024 before market open on May 8, 2024.
- Business Wire
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
RADNOR, Pa., April 15, 2024--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that an independent Data Monitoring Committee (DMC) has recommended continuing the pivotal Phase 3 RAISE trial evaluating intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE) following an interim analysis.
